Please note the ANZCTR will be unattended from Friday 20 December 2019 for the holidays. The Registry will re-open on Tuesday 07 January 2020. Submissions and updates will not be processed during that time.

Please be advised that as the ANZCTR is funded by Australia and New Zealand, we must prioritise submissions from these countries first. International submissions should allow additional time for registration. Apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12618000400268p
Ethics application status
Not yet submitted
Date submitted
6/03/2018
Date registered
20/03/2018
Date last updated
25/02/2019
Date data sharing statement initially provided
25/02/2019
Type of registration
Prospectively registered

Titles & IDs
Public title
Comparing high versus low dose of nebulised salbutamol in acute adult asthmatics presenting to the Emergency Department.
Scientific title
A non-inferiority comparison of low versus high salbutamol dosing regimens via nebusliser in severe to life-threatening exacerbations of adult asthmatics presenting to the emergency department: A randomised controlled trial.
Secondary ID [1] 294243 0
None
Universal Trial Number (UTN)
U1111-1210-2885
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Asthma 306922 0
Condition category
Condition code
Emergency medicine 306019 306019 0 0
Other emergency care
Respiratory 306076 306076 0 0
Asthma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
5mg salbutamol nebulisation every 20minutes over 1 hour. This will be directly observed by the investigator.
Intervention code [1] 300540 0
Treatment: Drugs
Comparator / control treatment
2.5mg salbutamol nebulisation every 20minutes over 1 hour.T his will be directly observed by the investigator.
Control group
Dose comparison

Outcomes
Primary outcome [1] 305053 0
FEV1 using bedside handheld spirometry.
Timepoint [1] 305053 0
At 60minutes post treatment protocol commencement,
Secondary outcome [1] 344001 0
FEV1 using bedside handheld spirometry.
Timepoint [1] 344001 0
At 20 and 40 minutes post treatment protocol commencement
Secondary outcome [2] 344191 0
Total dose of salbutamol administered at 120minutes post commencement of treatment protocol. This will be recorded by the attending clinician on the trial proforma.
Timepoint [2] 344191 0
120minutes post commencement of treatment protocol
Secondary outcome [3] 344192 0
Length of stay in ED. This will be monitored by the investigator.
Timepoint [3] 344192 0
When patient leaves the Emergency Department for another inpatient location or discharge from hospital.
Secondary outcome [4] 344193 0
Treatment failure defined as the need for non-invasive or invasive ventilation and IV salbutamol. This will be recorded by the investigator.
Timepoint [4] 344193 0
60minutes post commencement of treatment protocol
Secondary outcome [5] 344194 0
Adverse events: symptoms mirroring salbutamol toxicity, such as tremor, anxiety, uncharacteristic tachycardia or tachypnoea. These measures will be identified by the treating clinician and recorded by the investigator.
Timepoint [5] 344194 0
At 60minutes after commencement of the treatment protocol.

Eligibility
Key inclusion criteria
• Doctor diagnosis of asthma
• Age 18 to 65 years
• Presentation to ED with a severe asthma exacerbation
• PEF < 50% of predicted
• Concomitant asthma medication may include: none, ICS, ICS/LABA, theophylline, LTRA, oral steroids, sodium cromoglycate, nedocromil sodium
Minimum age
18 Years
Maximum age
65 Years
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
• Inability to perform spirometry
• Requirement for Non-invasive ventilation (NIV) or intubation at presentation
• Diagnosis of Chronic Obstructive Pulmonary Disease (COPD)

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation by computer generation to either trial drug A or B. Nebules will be masked by re-labeling the nebules either trial drug A or B. Masking will be carried out by the Pharmacy Department. The Investigators will not know what dose nebules A and B are.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Participants will be randomised 1:1 using a computer generated block randomisation sequence provided by the study biostatistician, incorporated into the electronic data capture system.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint(s)
Efficacy
Statistical methods / analysis
The statistical analysis will be by both intention to treat and per protocol by a biostatistician blinded to allocation. The primary outcome variable will be FEV1 measured after 60 minutes. The primary analysis will be ANCOVA with adjustment for baseline FEV1. Secondary outcomes will be FEV1, heart rate, respiratory rate and SpO2 at each time point, the total amount of nebulised salbutamol used in the first 2 hours, time in the ED, hospital admission, treatment failure (defined by the need for any of intravenous salbutamol, invasive or non-invasive ventilation, or ICU admission) and adverse events.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment outside Australia
Country [1] 9651 0
New Zealand
State/province [1] 9651 0
Wellington

Funding & Sponsors
Funding source category [1] 298882 0
Other
Name [1] 298882 0
Medical Research Institute of New Zealand
Address [1] 298882 0
Private Bag 7902
Wellington 6242

Level 7, CSB Building
Wellington Hospital
Riddiford St, Newtown
Wellington 6021
New Zealand
Country [1] 298882 0
New Zealand
Primary sponsor type
Other
Name
Medical Research Institute of New Zealand
Address
Private Bag 7902
Wellington 6242

Level 7, CSB Building
Wellington Hospital
Riddiford St, Newtown
Wellington 6021
New Zealand
Country
New Zealand
Secondary sponsor category [1] 298095 0
None
Name [1] 298095 0
Address [1] 298095 0
Country [1] 298095 0

Ethics approval
Ethics application status
Not yet submitted
Ethics committee name [1] 299824 0
Health and Disability Ethics Comission
Ethics committee address [1] 299824 0
Postal address:
Ministry of Health
Health and Disability Ethics Committees
PO Box 5013
Wellington 6140

Street address:
133 Molesworth Street
Thorndon
Wellington 6011
Ethics committee country [1] 299824 0
New Zealand
Date submitted for ethics approval [1] 299824 0
22/03/2018
Approval date [1] 299824 0
Ethics approval number [1] 299824 0

Summary
Brief summary
Despite extensive standard practice of the use of salbutamol in the treatment of acute asthma exacerbations, it is unclear how much should be given. This ambiguity has led clinicians to often give more than required salbutamol doses due to a perceived better outcome with higher doses. This can lead to multiple unpleasant side effects and reduces the tolerability of the treatment amongst patient groups.
We are carrying out a blinded randomised controlled trial to compare a higher dose against a lower dose of nebulised salbutamol in acute severe and life-threatening asthma presentations to the emergency department. We aim to compare several outcomes in both groups, including improvement in lung function, length of hospital stay, rates of admission to hospital and adverse events.
This is a non-inferiority study and we hypothesise that there will be no difference in outcome in both groups.
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 81682 0
Dr Saptarshi Mukerji
Address 81682 0
Emergency Department, Capital and Coast District Health Board
23 Mein Street
Newtown
Wellington
6021
Country 81682 0
New Zealand
Phone 81682 0
+64223128766
Fax 81682 0
Email 81682 0
sapimuk09@gmail.com
Contact person for public queries
Name 81683 0
Dr Saptarshi Mukerji
Address 81683 0
Emergency Department, Capital and Coast District Health Board
23 Mein Street
Newtown
Wellington
6021
Country 81683 0
New Zealand
Phone 81683 0
+64223128766
Fax 81683 0
Email 81683 0
sapimuk09@gmail.com
Contact person for scientific queries
Name 81684 0
Dr Saptarshi Mukerji
Address 81684 0
Emergency Department, Capital and Coast District Health Board
23 Mein Street
Newtown
Wellington
6021
Country 81684 0
New Zealand
Phone 81684 0
+64223128766
Fax 81684 0
Email 81684 0
sapimuk09@gmail.com

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
All data de-identified
When will data be available (start and end dates)?
After publication of results in peer reviewed journal. It is unclear at this early time point how long it would take to publish results. However, at an estimate data may be made available from December 2021 for a 12 month period.
Available to whom?
Available to appropriate institutions or individuals, who have appropriate clearances.
Available for what types of analyses?
Any
How or where can data be obtained?
Data will be electronic and can be shared on request.
What supporting documents are/will be available?
No other documents available
Summary results
No Results